Follistatin-344

Follistatin-344 is the circulating form of a protein the body uses to restrain myostatin, the principal brake on muscle growth. Because animals engineered to lack myostatin develop markedly more muscle, myostatin inhibition has been pursued as a way to increase muscle mass in conditions where muscle is lost. The human research is almost entirely gene therapy rather than injected protein: a single administration of a viral vector carrying the follistatin gene, tested in muscle-wasting conditions. The peptide sold to consumers borrows the reputation of that research without sharing its method or monitoring.

Myostatin is a signalling molecule that limits muscle growth. Follistatin-344 binds and neutralises myostatin as well as related ligands such as activin A, removing that brake on muscle development. Because it acts upstream of the muscle-building signal rather than providing a growth stimulus, the effect in animal models is an increase in muscle size and a change in fibre composition rather than a general anabolic drive.

• Increased muscle mass in animal models through myostatin inhibition
• Improved muscle function measures in a small gene-therapy trial in inclusion body myositis
• Well-characterised biology as an endogenous regulator of muscle growth
• Represents a genuinely different approach to muscle research

Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.

In animal models, increasing follistatin increases muscle mass substantially, and myostatin inhibition has been studied extensively in muscular dystrophies, sarcopenia and inclusion body myositis. A small human trial using AAV-delivered follistatin-344 in inclusion body myositis reported improvements in some muscle strength measures, which was notable as a proof of concept for the gene-therapy approach. Two important caveats follow. First, delivering a gene once is not the same as injecting a protein repeatedly, and the pharmacokinetics are entirely different. Second, several myostatin-inhibiting programmes have run into safety signals, particularly around blood-vessel formation at high doses. The evidence does not support casual use of injected follistatin for muscle gain.

• Injection-site reactions
• Joint and tendon discomfort reported by users
• Unknown cardiovascular effects at sustained high exposure
• No systematic human safety data

Atherosclerotic plaque and blood-vessel changes have been reported in some myostatin-inhibition programmes at high exposure, a serious signal. Follistatin influences activin and other transforming-growth-factor family ligands, so its effects extend beyond muscle. No human safety data exists for repeated injection of the peptide itself.

Discussed alongside other muscle-related compounds, none of which have been studied with it. Its mechanism is a brake release rather than a stimulus, so combining it with anabolic compounds compounds two unmonitored interventions.